WWM
CHRS icon

Willingdon Wealth Management’s Coherus Oncology CHRS Stock Holding History

Willingdon Wealth Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9
Closed – – 401
2019
Q3 		$0 Buy
+9
New +$180 ﹤0.01% 507

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Willingdon Wealth Management's CHRS Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 9 shares.

Willingdon Wealth Management first reported a position in CHRS in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 9 Coherus Oncology shares in Q4 2019.
  • Willingdon Wealth Management first reported a position in Coherus Oncology in Q3 2019 and held it in 1 quarter.
  • Willingdon Wealth Management's Coherus Oncology position peaked at $0 in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.